Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended June 30, 2006
Business Overview: Cardinal Health is a leading provider of products and services supporting the healthcare industry. As of June 30, 2006, operations were organized into four reportable segments: Pharmaceutical Distribution and Provider Services; Medical Products and Services; Pharmaceutical Technologies and Services; and Clinical Technologies and Services. The Company announced a restructuring of these segments effective for the fiscal year ending June 30, 2007, to align with two major business groups: Supply Chain Services and Pharmaceutical & Medical Products.
Key Financial Metrics
| Metric | Fiscal 2006 | Fiscal 2005 |
|---|---|---|
| Revenue | $81,363.6 million | $74,271.6 million |
| Operating Earnings | $1,966.7 million | $1,824.3 million |
| Net Earnings | $1,000.1 million | $1,050.7 million |
| Diluted EPS (Continuing Ops) | $2.90 | $2.54 |
| Diluted EPS (Net) | $2.33 | $2.41 |
| Cash Flow from Operating Activities | $2,140.3 million | $2,842.8 million |
| Total Assets | $23,374.1 million | $21,838.2 million |
| Long-term Obligations | $2,599.7 million | $2,319.9 million |
| Shareholders' Equity | $8,490.7 million | $8,593.0 million |
Note: Net earnings decreased 5% year-over-year primarily due to a $244.6 million loss from discontinued operations and increased equity-based compensation expenses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10% to a record $81.4 billion, driven by 11% growth in Pharmaceutical Distribution and 11% growth in Clinical Technologies.
- Operating Earnings: Increased 8% to $1.97 billion. Growth was led by the Clinical Technologies segment (up 56%) and Medical Products segment (up 4%). Pharmaceutical Distribution operating earnings were flat due to competitive pressures and a $31.8 million charge for vendor credits.
- Discontinued Operations: A significant $244.6 million loss was recorded in discontinued operations, primarily due to impairment charges of $237.4 million related to the Healthcare Marketing Services and Intercare Pharmaceutical Distribution businesses.
- Equity Compensation: Adoption of SFAS No. 123(R) resulted in a $237.3 million equity-based compensation expense in 2006, compared to $10.1 million in 2005.
- Share Repurchases: The Company repurchased approximately $1.5 billion of its common shares during fiscal 2006.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management emphasized a transition to a fee-for-service business model in Pharmaceutical Distribution, which moderates earnings seasonality. The Company expects selling, general, and administrative expenses to grow at a slower rate in fiscal 2007 due to changes in the equity compensation program and benefits from the "One Cardinal Health" restructuring initiative. A $2 billion share repurchase program was announced in August 2006.
Material Risks and Contingencies
- SEC Investigation: The Company is subject to a formal SEC investigation and a U.S. Attorney inquiry regarding accounting and financial reporting matters. The Company has reached an agreement-in-principle for a settlement involving a $35 million penalty ($25 million reserved in 2005, $10 million in 2006).
- Legal Proceedings: Multiple class action lawsuits (securities and ERISA) are pending. The Company cannot predict the outcome or potential loss range.
- Customer Concentration: CVS Corporation (21%) and Walgreen Co. (14%) accounted for 35% of total revenue. The top five customers accounted for 46% of revenue.
- Regulatory Risks: The Company faces risks related to healthcare fraud and abuse laws, Medicaid reimbursement formula changes, and FDA regulations. In August 2006, the FDA seized approximately 1,300 Alaris SE infusion pumps, leading to a suspension of production and sales pending a corrective action.
- Business Model Transition: The shift from price-inflation-based compensation to fee-for-service arrangements with pharmaceutical manufacturers reduces earnings volatility but exposes the Company to risks if price inflation slows.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the final sale price and timing for the Healthcare Marketing Services and Intercare Pharmaceutical Distribution businesses to assess the realization of the $237.4 million impairment charge.
- SEC Settlement Finalization: Monitor the finalization of the $35 million SEC settlement and any potential expansion of the investigation scope.
- Alaris SE Infusion Pump Resolution: Track the FDA approval of the keypad modification and any potential recall costs or revenue impact beyond the stated <1% of segment revenue.
- Customer Concentration: Assess the stability of relationships with CVS and Walgreens, which represent a significant portion of revenue and trade receivables.
- Equity Compensation Expense: Confirm that the high equity-based compensation expense of $237.3 million in 2006 is a one-time adoption impact and that future expenses will decline as projected.